In Phase A, individuals will get distinctive doses and schedules of oral ABBV-744 tablet to establish Harmless dosing regimen. Supplemental participants will be enrolled in the determined monotherapy dosign regimen. In Section B, individuals will get oral ruxolitinib and ABBV-744 will probably be supplied as "add-on" therapy. In Segment C, https://benitol665xis8.wikiinside.com/user